Veracyte Cash Flow Statement
NASDAQ: VCYTHealth CareMedical SpecialitiesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Veracyte free cash flow
In fiscal 2025, Veracyte generated $136.3 million of operating cash flow and spent $9.7 million on capital expenditures. That left free cash flow of $126.6 million, a free-cash-flow margin of 24.5% of revenue. Free cash flow was up 98.5% from the prior year's $63.8 million.
Summary generated from market data by MetaCap's automated system. Methodology
Veracyte cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 66.35M | 24.14M | -74.40M | -36.56M | -75.56M | -34.91M | -12.60M | -23.00M | -31.00M | -31.36M |
| Net Income growth (YoY) | +174.89% | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 21.41M | 23.46M | 27.19M | 25.93M | 19.59M | 7.94M | 4.12M | 3.92M | 3.84M | 3.51M |
| Stock-Based Compensation | 43.60M | 36.25M | 33.14M | 26.73M | 22.52M | 12.99M | 9.81M | 5.96M | 6.62M | 6.38M |
| Change in Working Capital | -6.66M | -17.88M | 1.60M | -5.96M | -8.20M | 1.76M | -9.55M | -615.00K | -4.09M | -6.88M |
| Operating Cash Flow | 136.31M | 75.10M | 44.22M | 7.54M | -31.62M | -9.71M | -3.23M | -13.52M | -23.91M | -27.98M |
| Capital Expenditures | -9.68M | -11.29M | -9.96M | -8.55M | -5.38M | -2.84M | -2.76M | -1.87M | -1.75M | -4.21M |
| Investing Cash Flow | -9.21M | -56.27M | 15.11M | -29.39M | -739.21M | -3.84M | -42.73M | -1.87M | -1.31M | -4.21M |
| Debt Issued | — | — | — | — | — | — | 0 | 0 | 24.88M | 24.45M |
| Debt Repaid | — | 0 | 0 | -1.28M | 0 | -100.00K | -24.90M | 0 | -25.39M | -5.00M |
| Financing Cash Flow | -4.22M | 4.90M | 2.84M | 3.49M | 596.32M | 203.59M | 127.29M | 59.50M | -218.00K | 52.33M |
| Net Change in Cash | 123.59M | 23.30M | 62.33M | -18.95M | -176.02M | 190.05M | 81.32M | 44.10M | -25.45M | 20.14M |
| Free Cash Flow | 126.63M | 63.81M | 34.26M | -1.01M | -37.00M | -12.55M | -5.99M | -15.39M | -25.67M | -32.19M |
This table shows 10 annual periods of Veracyte's cash flow statement, from FY 2025 back to FY 2016, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow VCYT's reporting calendar. What is a cash flow statement?